{"slug":"ss-31-tirzepatide","verification":{"valid":true,"entries":2,"head":"9dbf51aec5298c343ce51d4a4a531f0f785ef8d24a79a6f46407c637675976e1"},"energy":{"passes":2,"tokens_in":15019,"tokens_out":3190,"tokens_total":18209,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"9dbf51aec5298c343ce51d4a4a531f0f785ef8d24a79a6f46407c637675976e1"},"provenance":[{"ts":"2026-06-29T23:44:01.128Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Tirzepatide\nSlug: ss-31-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"},{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"},{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.","response":"{\n  \"slug\": \"ss-31-tirzepatide\",\n  \"title\": \"SS-31 (Elamipretide) and Tirzepatide: Mitochondrial Targeting and Metabolic Load Reduction\",\n  \"body\": \"## What's breaking down\\n\\nMitochondrial dysfunction can impair cellular energy production and increase oxidative stress across tissues. Separate from that, excess body weight increases compressive forces on the spine and joints during daily movement. Each extra pound of body weight can add roughly four pounds of force on lumbar structures. These layers operate independently; one does not automatically fix the other.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\nIf mitochondrial impairment is part of the picture, SS-31 is discussed because it binds cardiolipin in the inner mitochondrial membrane. This interaction is studied to stabilize the electron transport chain, lower reactive oxygen species, and support ATP output. Preclinical work in animal models shows restored mitochondrial respiration in heart, kidney, and muscle tissue. Human data come from trials in primary mitochondrial myopathy and Barth syndrome, where some functional measures improved after long-term use. The compound is examined for direct tissue-level repair rather than symptom masking.\\n\\n## Why Tirzepatide might help you\\n\\nIf elevated body weight contributes to mechanical overload, Tirzepatide is discussed because it activates GLP-1 and GIP receptors to promote substantial weight reduction. Clinical trials document average losses exceeding 15 percent of starting body weight in adults with or without type 2 diabetes. Reduced mass directly lowers the compressive load transmitted through the spine and weight-bearing joints with each step or lift. The pathway targets metabolic and mechanical factors, not direct analgesia or inflammation suppression at the joint surface.\\n\\n## How these fit together\\n\\nEach compound above targets a different degeneration layer. Together they are a stack — not copies of the same mechanism.\\n- SS-31 (Elamipretide) → mito","tokens_in":15019,"tokens_out":3190,"cost":0,"prev":"genesis","hash":"f9050219a578b20ce5c696e7e5d6264d30b408ee11af7adb626f15cfec792400"},{"ts":"2026-07-17T02:42:10.179Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-tirzepatide","response":"23 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f9050219a578b20ce5c696e7e5d6264d30b408ee11af7adb626f15cfec792400","hash":"9dbf51aec5298c343ce51d4a4a531f0f785ef8d24a79a6f46407c637675976e1"}]}